Illumina acquires ML-powered cancer detection firm Grail

By William Smith
Biotechnology giant Illumina has announced it is to acquire early cancer detection firm Grail...

Biotechnology giant Illumina has announced it is to acquire early cancer detection firm Grail.

The Silicon Valley-based company, founded in 2016, focuses on developing tests to detect multiple different types of cancer at an early stage - when successful treatment is much more likely.

The test involves taking a blood sample, which is then analysed via machine learning and data science techniques, alongside a database of cancer signatures. Grail’s Galleri platform is expected to launch commercially in 2021, with prior versions of the technology capable of detecting over 50 types of cancer and identify where in the body they are located

In a press release, Hans Bishop, Chief Executive Officer of Grail, said: “Cancer is one of society’s most significant challenges, with most cancer being detected too late. We believe multi-cancer early detection technology could address a tremendous unmet need and reduce the cancer burden worldwide. Combining forces with Illumina enables broader and faster adoption of Grail’s innovative, multi-cancer early detection blood test, enhancing patient access and expanding global reach.”

Grail was spun-out of Illumina, and went on to attract $2bn of investment across four funding rounds before being brought back into Illumina’s orbit. The deal, which has entered into a definitive agreement, involves cash and stock considerations totalling $8bn. 

Illumina gave its rationale for the purchase as tapping into the growing oncology market, as well as dovetailing with Illumina’s global scale to allow delivery of cancer tests to more patients, more quickly.

Francis deSouza, Illumina’s President and Chief Executive Officer, said: “Over the last four years, Grail’s talented team has made exceptional progress in developing the technology and clinical data required to launch the Galleri multi-cancer screening test. Galleri is among the most promising new tools in the fight against cancer, and we are thrilled to welcome Grail back to Illumina to help transform cancer care using genomics and our NGS platform.”

Share

Featured Articles

Lenovo: Employees prefer mix of AI and human IT support

New Lenovo survey shows 91% of employees believe they would be more productive when their IT issues at work are resolved quickly and effectively

Kyndryl’s Data and AI Console to simplify data management

Data-driven solution expands and increases observability and insights, while enhanced data governance helps identify irregularities and threats

Deep neural networks still struggling to match human vision

New study by researchers in Canada finds artificial intelligence still can't match the powers of human vision despite deep learning's ability with big data

Metaverse destined to become an impossible, dangerous place

Technology

Clever coders lead the way as Microsoft launches 365 Copilot

AI Applications

Baidu’s ERNIE doesn’t want confrontation with United States

AI Applications